How GLP-1 telehealth programs work: what to look for, what to avoid
A GLP-1 telehealth program is a licensed medical practice that prescribes GLP-1 medication remotely and ships either branded medication from a pharmacy or compounded medication from a 503A compounding pharmacy. About 25 US programs operate at meaningful scale in 2026. They differ across five dimensions we score consistently. We walk through what each program is, how it operates, what good and bad ones look like, and when to use a local clinic instead.
The short version
A GLP-1 telehealth program is a licensed medical practice that prescribes remotely and ships medication from a partner pharmacy. The category has roughly 25 US programs operating at meaningful scale in 2026. They differ across five dimensions we score consistently: pricing transparency, cancellation terms, onboarding experience, medication options and member outcomes. The branded path uses an insurance pathway for Wegovy, Zepbound, Ozempic or Mounjaro. The compounded path is cash-pay for 503A-pharmacy-prepared semaglutide or tirzepatide. Lock-in ranges from none (Sesame visit-by-visit) to six-month commitment with auto-renewal. Synchronous video visits are clinically richer; asynchronous form-based intake is faster. The most important practical point: every program operates as a licensed medical practice subject to state telehealth regulations, not as a pharmacy or retailer.
Key facts
| Dimension | What good looks like | What bad looks like | Where we score it |
|---|---|---|---|
| Pricing transparency | Maintenance-dose price published; labs, intake and shipping itemized | Starter-dose teaser; fees revealed at checkout | Price Index |
| Cancellation | Self-serve cancel inside the dashboard; no lock-in past current month | Phone-only cancel; six-month upfront non-refundable | Contract traps |
| Onboarding | Intake to first dose under 5 days; synchronous visit option | 14+ day delay; no clinician contact past initial form | Fastest programs |
| Medication options | Branded + compounded path; dose flexibility | Single tier; no titration support | Compounded vs branded |
| Member outcomes | Trustpilot, Reddit, community feedback consistent | Complaints about delivery, support, billing | Methodology |
We score every program in the chart against these five dimensions, ten points each, weighted equally. Full methodology and rubric: scoring methodology.
What a GLP-1 telehealth program actually is
A GLP-1 telehealth program in 2026 is a US-based medical practice (often organized as a Professional Corporation or PC owned by physicians and contracted with a parent administrative entity) that operates remotely. The patient creates an account, completes a medical-history intake, has either an asynchronous review or a synchronous video visit with a licensed prescriber, and receives a prescription that is dispensed by a partner pharmacy. The medication ships to the patient, refrigerated where required. Most programs include ongoing prescriber availability for dose adjustment and side-effect management; some charge separately for follow-up visits.
The regulatory framework is state telemedicine law. Each prescriber must be licensed in the state where the patient lives. Programs achieve this through the Interstate Medical Licensure Compact (IMLCC) and through hiring networks of prescribers licensed in multiple states. The DEA telemedicine rules for controlled substances (see the DEA proposed telemedicine rule) do not apply to GLP-1 (these molecules are not controlled), which simplifies the operational picture. Programs are not pharmacies, do not hold medication inventory directly, and do not employ pharmacists; the partner pharmacy handles dispensing under the regulatory frameworks for 503A and 503B compounding (see FDA's compounding laws and policies).
Branded vs compounded path
The single biggest structural decision a program makes is whether to offer the branded path, the compounded path, or both. The branded path runs an insurance-pathway intake: the prescriber writes for Wegovy, Zepbound, Ozempic or Mounjaro, the program supports a prior authorization where coverage is available, and the medication ships from a retail or specialty pharmacy. Cost is whatever the patient's insurance copay is or whatever the cash-pay manufacturer-direct program (NovoCare, LillyDirect) charges. The compounded path is cash-pay only; the prescriber writes for compounded semaglutide or tirzepatide, the prescription is dispensed by a 503A compounding pharmacy, and the patient pays the program's flat monthly fee. The branded path is the only path that produces an insurance-covered outcome. The compounded path is the only path that produces a predictable sub-$350 monthly cost. The FDA published its position on these molecules' compounding eligibility in its semaglutide compounding statement and a parallel tirzepatide statement. About 12 of our 25 scored programs offer only one path; about 13 offer both. See compounded vs FDA-approved semaglutide for the clinical distinction and generic semaglutide launch for the 2026 supply context.
The five dimensions we score
Our methodology scores every program against five dimensions, ten points each, weighted equally. The scoring is published in full at methodology and the per-program score-sheet is on each program page.
- Pricing transparency. Maintenance-dose cost published, ongoing rate separated from introductory rate, lab and setup fees disclosed at the homepage rather than the checkout. A program that hides the maintenance price behind an intake gate scores low; a program that lists both starter and maintenance prices on the pricing page scores high.
- Cancellation terms. Self-serve cancellation in the patient dashboard with no phone-only friction. Lock-in past the current paid month is penalized in proportion to length and refundability. The contract-traps glossary at seven contract traps covers the full taxonomy.
- Onboarding experience. Time from intake start to first prescription. Quality of the clinical assessment (intake-form depth, presence of synchronous visit option). Friction at intake. Programs that ship the first dose within five business days score well; programs that take two weeks to first dose score low. Time-sensitive sort: fastest GLP-1 programs.
- Medication options. Branded availability, compounded availability, insurance pathway support, dose flexibility (can the patient hold or step back during titration). Programs that offer both branded and compounded with active dose flexibility score highest.
- Member outcomes. Trustpilot, Reddit, program-specific community feedback weighted above marketing copy. We read patient feedback for every program. Where the verified-member feedback is sparse, we discount the score rather than score from marketing alone.
Lock-in terms decoded
Lock-in is the contract term that requires the patient to pay for a multi-month commitment upfront, often with limited refund rights. The taxonomy is small: no lock-in (true month-to-month or visit-by-visit), soft lock-in (one to three month commitment, refundable on cancellation), medium lock-in (three to six months upfront, non-refundable after the first 14 days), hard lock-in (six months upfront non-refundable with auto-renewal), and the worst variant: hard lock-in with phone-only cancellation. Programs that score highest on cancellation have either no lock-in or soft lock-in plus self-serve cancellation. The deep dive is at what no lock-in actually means and the no-lock-in cluster at best no-lock-in programs. The contract patterns we have flagged across programs are at contract traps.
Synchronous vs asynchronous visits
Synchronous (live video) visits and asynchronous (form-based) intake serve different patient needs. Asynchronous is faster and works for healthy adults with straightforward obesity and no complicating medical history; the intake form captures the key clinical data, the prescriber reviews on their own schedule, and the prescription is written. Synchronous is clinically richer; the prescriber can ask follow-up questions, observe the patient, and address concerns in real time. The 2020 to 2023 surge in telehealth volume was largely asynchronous (it scales better); the regulatory picture in 2024 to 2026 is gradually tilting back toward at least one synchronous visit before initial prescription. The Department of Health and Human Services Office of the National Coordinator for Health IT publishes telehealth guidance at telehealth.hhs.gov, and the Centers for Medicare and Medicaid Services maintains the federal payment policy for asynchronous and synchronous telemedicine at the CMS telehealth coverage page. California, New York, Texas and Florida have stricter state-level standards. Most programs now offer at least an optional synchronous visit; some require it. The clinical case for synchronous is in primary care vs telehealth.
How to evaluate a program before signing up
Five checks before paying anything. First, find the maintenance-dose price, not the starter price; if the program does not publish it openly, that is a signal. Second, find the cancellation procedure (self-serve in the dashboard, or phone-only, or written notice required); cancellation friction is the single best predictor of post-purchase regret. Third, identify the prescribing entity by name and confirm state licensure; legitimate programs publish this. Fourth, identify the dispensing pharmacy by name; for compounded medication, confirm it is a US-based 503A pharmacy. Fifth, search Reddit, Trustpilot and the program-specific community feedback for billing, shipping and clinical-support complaints. The red-flags checklist is at red flags checklist.
Signs of a bad program
Patterns that consistently predict poor outcomes: phone-only cancellation, opaque maintenance pricing, no synchronous visit option for a patient with any complicating history, no published prescriber name, shipping from an unidentified pharmacy, marketing language that promises specific weight-loss outcomes ("lose 20 pounds in 30 days"), aggressive auto-renewal, and a refund policy that starts at "no refunds." None of these are inherently illegal but they consistently correlate with the lowest member-satisfaction scores in the chart. Reputable programs in the chart fail one or two of these checks at most; problem programs fail four or five.
What to do if your program raises prices
Programs do raise prices. The most common pattern in 2025 to 2026 was a $50 to $100 a month increase on compounded programs as API costs and 503A regulatory overhead rose. The 30-day notice is the standard. If the new price still beats your alternatives, accept and continue. If the new price puts the program above its peers, switch. Switching guidance is in switching from compounded to brand and the program-to-program switching path in when your insurance changes. Most programs will negotiate retention if asked, especially within 24 hours of cancellation; the leverage is small but real.
Switching programs without clinical discontinuity
Switching programs is straightforward when the new program is reputable. Bring three pieces of information to the new program's intake: current dose (semaglutide or tirzepatide milligrams per week), date of most recent injection, and titration history (which dose you started at, when you stepped up). The new program picks up the titration where the prior program left off; reputable programs do not force restart at the starter dose. The two-week gap during transfer is tolerable for most patients; longer gaps may require a brief restart at one dose below the current dose to retitrate. The clinical principle is dose continuity wherever possible.
When to use a local clinic instead
Local in-person care is the better default for several patient profiles. Complex medical history that benefits from a clinician who can see the full record: prior pancreatitis, heart failure, advanced kidney disease, type 1 diabetes, recent bariatric surgery. Need for in-person physical examination (some commercial plans now require it). Existing relationship with an obesity medicine specialist or endocrinologist. Insurance coverage available at a local clinic but not through a telehealth program. Patient preference for in-person clinical relationships. Pediatric or adolescent patient (most telehealth programs are adults only). The full comparison is in primary care vs telehealth GLP-1.
State telemedicine rules that affect program operation
Telemedicine rules vary by state, and the variation creates the patchwork of program availability across the US. The largest legal source is each state's Medical Practice Act and the state Medical Board's telemedicine policy. The Federation of State Medical Boards maintains a national tracker (see FSMB telemedicine policy summary). California, New York, Texas and Florida have stricter standards (typically requiring at least one synchronous visit and a documented clinician-patient relationship before prescription). Other states are more permissive. Federal DEA telemedicine rules around controlled-substance prescribing do not apply to GLP-1 because these molecules are not controlled substances; the DEA's evolving rules on telehealth prescribing affect other drug categories (Adderall, testosterone) but not GLP-1. Programs disclose their state availability on the signup flow; the gap-states (where a program does not operate) is captured in the chart's state-availability filter.
What the trial evidence supports about program delivery
Most randomized trial evidence on GLP-1 (STEP, SURMOUNT, SELECT, SURPASS) was generated under traditional in-person clinical care, not telehealth. There is no large randomized trial directly comparing telehealth GLP-1 delivery to in-person delivery. Observational data from large telehealth networks suggests outcomes are broadly comparable when titration is well-managed and patient adherence is similar; the variance is largely driven by patient factors (baseline BMI, adherence, lifestyle support) rather than delivery channel. The behavioral support component of obesity care, where telehealth programs vary widely (some include intensive coaching, some include none), may matter more than the prescription itself for long-term outcomes. The STEP-3 trial (intensive behavioral therapy plus semaglutide) is published at JAMA; the SURMOUNT-1 trial is at NEJM. The trial backbone is the same regardless of delivery channel.
Program picks by buyer scenario
We do not recommend "the best program" in the abstract because the right program depends on the patient scenario. For cheapest cash-pay compounded, see cheapest programs and under $200. For fastest time to first dose, see fastest programs and fastest onboarding. For no lock-in, see no lock-in programs. For Wegovy specifically (branded path) see best for Wegovy; for Zepbound see best for Zepbound. For Medicare cardiovascular indication, see Medicare CV pathway; for Medicaid patients, see Medicaid-friendly programs. Specific program deep-dives at Mochi, Henry Meds, Hims, Ro, Form Health, Found, Calibrate, Ivim Health, Eden, LifeMD, Sesame Care, PlushCare, 9am Health and Knownwell.
What to do next
If you have a clear scenario in mind (cheapest, fastest, branded with insurance, no lock-in), pick the matching cluster page above and start there. If you want the full ranked chart, the homepage chart at homepage compare ranks all 25 programs against the same five dimensions and sorts by overall score and by maintenance-dose price. If you want to understand the underlying scoring rubric before trusting it, the methodology page walks through each dimension. If you want to see what we found at this week's price walkthrough, the latest quarterly numbers are at Price Index. The cost pillar at GLP-1 cost and the insurance pillar at GLP-1 insurance are companions to this page.
